A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
Temozolomide (TMZ) resistance in glioblastomas (GBM) is associated with increased MGMT expression. Here, the authors identify an enhancer between the promoters of MKI67 and MGMT, that when activated drives MGMT expression despite MGMT promoter methylation to confer TMZ resistance in GBM.
Guardado en:
Autores principales: | Xiaoyue Chen, Minjie Zhang, Haiyun Gan, Heping Wang, Jeong-Heon Lee, Dong Fang, Gaspar J. Kitange, Lihong He, Zeng Hu, Ian F. Parney, Fredric B. Meyer, Caterina Giannini, Jann N. Sarkaria, Zhiguo Zhang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e9cbaa57340b40429d4d685a036a322c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Advances in the management of glioblastoma: the role of temozolomide and MGMT testing
por: Thomas RP, et al.
Publicado: (2012) -
Lack of Benefit of Extending Temozolomide Treatment in Patients with High Vascular Glioblastoma with Methylated <i>MGMT</i>
por: María del Mar Álvarez-Torres, et al.
Publicado: (2021) -
Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide)
por: Arshad A. Pandith, et al.
Publicado: (2018) -
Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide
por: Yiming Ding, et al.
Publicado: (2021) -
Novel cancer stem cell marker MVP enhances temozolomide-resistance in glioblastoma
por: Kum Hee Noh, et al.
Publicado: (2022)